Explore › Outcome › Hepatocellular carcinoma
Outcome

Hepatocellular carcinoma

Also known as: Adult Liver Cancer Adult Liver Cancers Cancer, Adult Liver Cancers, Adult Liver Carcinoma, Hepatocellular Carcinoma, Liver Cell Carcinomas, Hepatocellular Carcinomas, Liver Cell Cell Carcinoma, Liver Cell Carcinomas, Liver HCC - Hepatocellular carcinoma Hepatocarcinoma +31 more
18 findings 1 paper 10 related entities View in graph →

Related entities

interventions
Metformin1 insulin monotherapy1 Lispro insulin in parenteral dosage form1 Hypoglycemic Sulfonylureas1 Glycemic Control1 Presence of1
conditions
Metastatic hepatocellular carcinoma5 Non-alcoholic Fatty Liver Disease1
populations
Type 2 Diabetes Patients6
studys
PMC91075296

Findings (50)

None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, use of insulin in combination with oral diabetes medications was associated with a 1.5 to 1.7-fold higher risk of hepatocellular carcinoma compared with no medicat

Effect: decline; HR 1.53; CI: 95% CI 1.26-1.86

Size: HR 1.53 CI: 95% CI 1.26-1.86
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →
None
decline

In patients with NAFLD and diabetes, the presence of diabetes complications was associated with a 24% higher risk of hepatocellular carcinoma.

Effect: decline; HR 1.24; CI: 95% CI 1.12-1.38

Size: HR 1.24 CI: 95% CI 1.12-1.38
PMC9107529
Finding details → · Paper → · Graph →

Papers (1)